BBH stock forecast, quote, news & analysis

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT).

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

The average market capitalization across the VanEck Biotech ETF ETF is 33B. The market cap for tickers in the group ranges from 4.03B to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is CRSP at 4.03B.

The average weekly price growth across all stocks in the VanEck Biotech ETF ETF was -10%. For the same ETF, the average monthly price growth was -11%, and the average quarterly price growth was -6%. NTRA experienced the highest price growth at 9%, while MRNA experienced the biggest fall at -21%.

The average weekly volume growth across all stocks in the VanEck Biotech ETF ETF was 72%. For the same stocks of the ETF, the average monthly volume growth was 237% and the average quarterly volume growth was 196%